You are here
|Splicing mutations in human genetic disorders: Review||
This is an open-access review covering the mechanism of eukaryotic RNA splicing and diseases caused by mutations in regions affecting splicing.
Abramowicz A, Gos M. Splicing mutations in human genetic disorders: examples, detection, and confirmation. J Appl Genet. 2018. doi: 10.1007/s13353-018-0444-7
|Tuesday, April 24, 2018 - 08:55|
|Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds (review)||
|Monday, April 23, 2018 - 07:33|
|BLAST homology: screening predicted specificity||
It is always prudent to screen proposed oligo sequence for potential off-target RNA interactions using BLAST. Partial homologies between a Morpholino's inverse complement and an RNA which are reported by BLAST are often in regions of the RNA where binding a Morpholino is unlikely to alter gene expression. If there is significant homology in a region where binding a Morpholino is likely to alter a transcript's expression, have us design another oligo.
|Thursday, April 5, 2018 - 09:31|
|Fish mutant, where is thy phenotype?||
"Due to genetic compensation, phenotypically wild-type mutants can become refractive to morpholino-induced phenotypes, providing a critical test both for genetic compensation and for the specificity of morpholino phenotypes."
Balciunas D. Fish mutant, where is thy phenotype? PLoS Genet. 2018;14(2):e1007197.
|Thursday, February 22, 2018 - 11:40|
|Cardiac Ventricular Injection in Zebrafish Larva||
This is an interesting technique for later-stage zebrafish embryo treatment, involving pulsed injection of a mixture of Morpholino and Endo-Porter into the heart. I think this might push the limit of solubility for many Morpholino sequences. They are reporting good systemic delivery -- see the video for fluorescent images of the oligo distribution.
|Wednesday, February 14, 2018 - 15:27|
|Patent on central nervous system delivery of Morpholinos by low osmolar contrast agents||
This one looks interesting. Morpholino and 2'-MOE activities are compared in SMA models.
United States Patent Application 20180030443
NON-IONIC, LOW OSMOLAR CONTRAST AGENTS FOR DELIVERY OF ANTISENSE OLIGONUCLEOTIDES AND TREATMENT OF DISEASE
|Wednesday, February 7, 2018 - 11:43|
|Skipping Multiple Exons: Review of DMD Morpholino, Vivo-Morpholino & PPMO work||
Review of DMD multiple exon skipping with Morpholino, Vivo-Morpholino & PPMO by Toshifumi Yokota's group.
Skipping Multiple Exons to Treat DMD-Promises and Challenges.
Aslesh T, Maruyama R, Yokota T.
Biomedicines. 2018 Jan 2;6(1). pii: E1. doi: 10.3390/biomedicines6010001. Review.
|Monday, January 8, 2018 - 07:46|
|Morpholino-based skipping of an exon caused inclusion of another exon, following that transcript's pattern of normal alternative splicing.||
Here is an example of an unusual outcome from modifying splicing. Vivo-Morpholinos targeting exon 9 caused skipping of exon 9 and inclusion of exon 10. In normal alternative splicing of this RNA, either exon 9 is included and exon 10 is excised (Pkm1) or exon 9 is excised and exon 10 is excluded (Pkm2).
|Wednesday, December 20, 2017 - 12:00|
|Gel retardation assay using RNA with a complementary Morpholino||
This image is of a gel retardation assay using RNA with a complementary Morpholino altering its migration.
|Tuesday, December 19, 2017 - 14:15|
|Paper: Hybrid splicing minigene and antisense oligonucleotides as efficient tools to determine functional protein/RNA interactions||
This paper describes setting up systems to determine splicing-related protein-RNA interactions; this might be especially useful for confirming whether a particular putatuve splice-regulatory protein binding site is actually involved in modulating splicing. The oligos reported were not Morpholinos, but I expect this system would be compatible with Morpohlinos.
Hybrid splicing minigene and antisense oligonucleotides as efficient tools to determine functional protein/RNA interactions.
Cywoniuk P, Taylor K, Sznajder ŁJ, Sobczak K.
|Monday, December 18, 2017 - 09:18|